Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy

"Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro and in vivo studies to increase both gastric and colon motility. In a case-control study of patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas passing and defecation time.

Recently, a study reported that mosapride citrate acts on the α7nACh receptor and, consequently, suppresses the inflammatory response of macrophages, thereby suppressing the mechanism that induces paralysis after surgery.

To date, this study is intended to analyze whether mosapride citrate significantly affects the improvement of bowel movement after surgery after gastrectomy."

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stomach Cancer Cicatrix Digestive System Diseases Digestive System Neoplasms Fibrosis Gastrointestinal Diseases Gastrointestinal Neoplasms Ileus Intestinal Diseases Intestinal Obstruction Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Stomach Diseases Stomach Neoplasms Tissue Adhesions

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

GangnamSeverance Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with gastric cancer pathologically before surgery
Patients who underwent surgical resection (R0 resection)
Patients with an ASA score of 3 or less

Exclusion criteria

Patients over 80 years old
When there are multiple or peritoneal metastases
Intestinal obstruction before surgery
When chemotherapy was performed before surgery
When cancer other than stomach cancer is diagnosed
If you have a long history of major intra-abdominal surgery or a history of abdominal radiotherapy
In case of liver failure or kidney failure
When it is judged that uncontrolled diabetes may affect intestinal function

Treatment and study plan

Mosapride citrate

Drug

Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.

Placebo

Drug

Placebo

Primary outcomes

The number of radiopaque markers transferred to the large intestine 3 days after surgery

Time frame: 3 Days after surgery

Intestinal motility after gastrectomy

Sponsors and collaborators

Lead sponsor

Gangnam Severance Hospital

Other

Registry information

Official study title

The Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy: Prospective, Double Blind Placebo-controlled Study

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Jul 30, 2020
Registry last updated: Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed